X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3308) 3308
Publication (469) 469
Book Review (67) 67
Book Chapter (39) 39
Dissertation (10) 10
Conference Proceeding (4) 4
Book / eBook (2) 2
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1878) 1878
humans (1508) 1508
animals (1366) 1366
signal transduction (834) 834
jak (719) 719
mice (600) 600
cell biology (596) 596
jak/stat pathway (559) 559
biochemistry & molecular biology (553) 553
phosphorylation (528) 528
male (494) 494
activation (493) 493
expression (476) 476
oncology (465) 465
apoptosis (425) 425
immunology (413) 413
female (410) 410
signal transduction - drug effects (395) 395
proteins (369) 369
cytokines (365) 365
jak-stat (365) 365
stat (364) 364
pharmacology & pharmacy (351) 351
jak-stat pathway (350) 350
analysis (349) 349
jak/stat (339) 339
stat3 transcription factor - metabolism (338) 338
janus kinases - metabolism (323) 323
cancer (317) 317
gene expression (308) 308
article (302) 302
inflammation (302) 302
janus kinase (294) 294
stat3 (293) 293
kinases (290) 290
jak inhibitor (281) 281
hematology (279) 279
rats (275) 275
gene-expression (267) 267
stat transcription factors - metabolism (259) 259
cell line, tumor (249) 249
cells, cultured (248) 248
research (240) 240
cell line (239) 239
tofacitinib (234) 234
signal transduction - physiology (227) 227
nf-kappa-b (215) 215
rheumatoid arthritis (214) 214
cells (208) 208
janus kinase 2 (207) 207
health aspects (205) 205
dna-binding proteins - metabolism (196) 196
mutation (195) 195
trans-activators - metabolism (193) 193
interferon (192) 192
janus kinase 2 - metabolism (189) 189
jak inhibitors (188) 188
pathway (188) 188
janus kinases - antagonists & inhibitors (187) 187
receptor (186) 186
genetic aspects (181) 181
transcription (180) 180
protein-tyrosine kinases - metabolism (177) 177
middle aged (172) 172
blotting, western (171) 171
proliferation (167) 167
protein kinase inhibitors - pharmacology (167) 167
medicine, research & experimental (163) 163
ruxolitinib (163) 163
adult (160) 160
cell proliferation (159) 159
inhibition (159) 159
rheumatology (152) 152
apoptosis - drug effects (151) 151
growth (149) 149
leukemia (149) 149
cytokines - metabolism (148) 148
care and treatment (144) 144
cytokine (142) 142
medicine & public health (142) 142
phosphorylation - drug effects (142) 142
signal-transduction (142) 142
neurosciences (141) 141
stat1 transcription factor - metabolism (141) 141
genes (140) 140
in-vivo (139) 139
protein kinase inhibitors - therapeutic use (138) 138
differentiation (136) 136
gene (136) 136
transcription factors (136) 136
protein (135) 135
interleukin-6 (134) 134
oxidative stress (134) 134
review (134) 134
janus kinase 2 - antagonists & inhibitors (133) 133
physiological aspects (133) 133
myelofibrosis (132) 132
research article (132) 132
biology (131) 131
ifn-gamma (126) 126
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3296) 3296
German (13) 13
French (6) 6
Russian (6) 6
Chinese (5) 5
Japanese (5) 5
Korean (4) 4
Polish (2) 2
Portuguese (2) 2
Serbian (1) 1
Spanish (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Dermatologic Therapy, ISSN 1396-0296, 11/2017, Volume 30, Issue 6, pp. e12555 - n/a
The rapid progress of genetic engineering furthermore opens up new prospects in the therapy of this difficult‐to‐treat disease. IL‐23 inhibitors,... 
treatment | PDE4 inhibitors | psoriasis | therapy | biological drugs | immune‐modulating | IL‐23 inhibitors | JAK inhibitors | IL-23 inhibitors | immune-modulating | CONTROLLED-TRIAL | MODERATE | EFFICACY | SAFETY | PHASE-III | GUSELKUMAB | INTERLEUKIN-23 | DERMATOLOGY | APREMILAST | PLAQUE PSORIASIS | TILDRAKIZUMAB | Interleukin-23 Subunit p19 - antagonists & inhibitors | Humans | Psoriasis - diagnosis | Dermatologic Agents - therapeutic use | Janus Kinases - metabolism | Molecular Targeted Therapy | Dermatologic Agents - adverse effects | Interleukin-23 Subunit p19 - metabolism | Phosphodiesterase 4 Inhibitors - adverse effects | Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism | Skin - pathology | Skin - immunology | Psoriasis - immunology | Psoriasis - drug therapy | Phosphodiesterase 4 Inhibitors - therapeutic use | Treatment Outcome | Skin - enzymology | Janus Kinases - antagonists & inhibitors | Janus Kinase Inhibitors - adverse effects | Animals | Janus Kinase Inhibitors - therapeutic use | Signal Transduction - drug effects | Cyclic Nucleotide Phosphodiesterases, Type 4 - immunology | Interleukin-23 Subunit p19 - immunology | Psoriasis - enzymology | Skin - drug effects | Psoriasis | Interleukins | Dermatology | Formulae, receipts, prescriptions | Monoclonal antibodies | Mutual fund industry | Dermatologic agents | Genetic engineering | Drug therapy
Journal Article
Bioorganic & Medicinal Chemistry Letters, ISSN 0960-894X, 10/2014, Volume 24, Issue 19, pp. 4617 - 4621
Journal Article
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 8/2016, Volume 113, Issue 35, pp. 9852 - 9857
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 09/2015, Volume 58, Issue 18, pp. 7596 - 7602
Journal Article
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, ISSN 0012-0472, 06/2019, Volume 144, Issue 11, pp. 748 - 752
In Germany, baricitinib and tofacitinib have been approved for the treatment of at least moderately active rheumatoid arthritis after the failure of... 
MEDICINE, GENERAL & INTERNAL | PLACEBO | Tofacitinib | ADALIMUMAB | DISEASE | METHOTREXATE | ARTHRITIS | COMBINATION | rheumatoid arthritis | JAK inhibitors | Baricitinib
Journal Article
Journal of Clinical Gastroenterology, ISSN 0192-0790, 10/2019, Volume 53, Issue 9, pp. 635 - 640
BACKGROUND:The treatment of ulcerative colitis (UC) is based on conventional therapies (aminosalicylates, corticosteroids, and immunosuppressants) and when... 
RHEUMATOID-ARTHRITIS | JAK INHIBITORS | MORTALITY | INFECTIONS | inflammatory bowel diseases | SAFETY | MECHANISMS | INDUCTION | MAINTENANCE THERAPY | tofacitinib | oral treatment | INFLAMMATORY-BOWEL-DISEASE | Janus kinase inhibitors | ulcerative colitis | GASTROENTEROLOGY & HEPATOLOGY
Journal Article
American Journal of Transplantation, ISSN 1600-6135, 08/2009, Volume 9, Issue 8, pp. 1936 - 1945
This randomized, pilot study compared the Janus kinase inhibitor CP-690,550 (15 mg BID [CP15] and 30 mg BID [CP30], n = 20 each) with tacrolimus (n = 21) in de... 
kidney | immunosuppression | transplant | inhibitor | Janus kinase (JAK) | CP-690,550 | CP‐690,550 | Immunosuppression | Inhibitor | Kidney | Transplant | NONHUMAN-PRIMATES | SURGERY | RENAL-TRANSPLANTATION | TRANSPLANTATION | 550 | REJECTION | CP-690 | MYCOPHENOLATE-MOFETIL | SIROLIMUS | Kidney Transplantation - pathology | Follow-Up Studies | Kidney - pathology | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Adrenal Cortex Hormones - therapeutic use | Glomerular Filtration Rate - physiology | Transplantation, Homologous | Dose-Response Relationship, Drug | Young Adult | Calcineurin Inhibitors | Kidney Transplantation - physiology | Piperidines | Pyrroles - adverse effects | Adult | Female | Drug Therapy, Combination | Pyrroles - therapeutic use | Kidney - physiopathology | Graft Rejection - prevention & control | Kaplan-Meier Estimate | Tacrolimus - adverse effects | Janus Kinases - antagonists & inhibitors | Adrenal Cortex Hormones - adverse effects | Mycophenolic Acid - adverse effects | Tacrolimus - therapeutic use | Pilot Projects | Mycophenolic Acid - analogs & derivatives | Mycophenolic Acid - therapeutic use | Biopsy | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Immunosuppressive Agents - adverse effects | Aged | Graft Rejection - immunology | Kidney Transplantation - immunology | Virus diseases | Medical colleges | Kidneys | Tacrolimus | Anemia | Immunotherapy | Transplantation | Kidney diseases | Health aspects | Index Medicus
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2016, Volume 76, Issue 4, pp. 736 - 744
New molecularly targeted therapeutics are changing dermatologic therapy. Janus kinase–signal transducer and activator of transcription (JAK-STAT) is an... 
Dermatology | JAK-STAT | psoriasis | baricitinib | vitiligo | atopic dermatitis | JAK inhibitor | ruxolitinib | alopecia areata | tofacitinib | RHEUMATOID-ARTHRITIS | OCLACITINIB APOQUEL(R) | OPEN-LABEL | DERMATOLOGY | LONG-TERM EXTENSION | PHASE 2B TRIAL | ALOPECIA-AREATA | ATOPIC-DERMATITIS | JANUS KINASE INHIBITOR | PLAQUE PSORIASIS | TOFACITINIB CITRATE | Pyrazoles - therapeutic use | Dermatitis, Atopic - enzymology | Humans | Dermatologic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Dermatologic Agents - adverse effects | Anti-Inflammatory Agents - adverse effects | Anti-Inflammatory Agents - therapeutic use | Pyrroles - adverse effects | Vitiligo - drug therapy | Pyrroles - therapeutic use | Pyrazoles - adverse effects | Psoriasis - drug therapy | Vitiligo - enzymology | Azetidines - adverse effects | Alopecia Areata - enzymology | Skin Diseases - drug therapy | Clinical Trials as Topic | Dermatologic Agents - classification | Janus Kinases - antagonists & inhibitors | Dermatitis, Atopic - drug therapy | Alopecia Areata - drug therapy | Azetidines - therapeutic use | Signal Transduction - drug effects | Sulfonamides - therapeutic use | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Piperidines - adverse effects | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Psoriasis - enzymology | Skin Diseases - enzymology | Medical colleges | Psoriasis | Atopic dermatitis | Formulae, receipts, prescriptions | Dermatologic agents | Pharmaceutical industry | Tyrosine | Interleukins | Interferon | Biological response modifiers | T cells | Tofacitinib
Journal Article
European Journal of Medicinal Chemistry, ISSN 0223-5234, 11/2019, Volume 182, p. 111664
As an important source of drugs, natural products play an important role in the discovery and development of new drugs. More than 60% of anti-tumor drugs are... 
Natural products | JAK-STAT | VEGFR | PDGFR | Bcr-Abl | HER-2/neu | c-Met(HGFR) | IGF-1R | FGFR | Tyrosine kinase inhibitors | EGFR
Journal Article